2022
Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment
Bikdeli B, Khairani CD, Barns BM, Rosovsky RP, Jimenez D, Monreal M, Sylvester KW, Middeldorp S, Bates SM, Krumholz HM, Goldhaber SZ, Hunt BJ, Piazza G. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials 2022, 115: 106714. PMID: 35202841, DOI: 10.1016/j.cct.2022.106714.Peer-Reviewed Original Research
2016
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.Peer-Reviewed Original ResearchConceptsHospital referral regionsOral anticoagulantsReferral regionsDiabetes drugsDrug classesGreater prescribingMedicare Part D beneficiariesAdditional daysPart D beneficiariesMedicare Part D prescriptionsCross-sectional analysisSectional ecological studyMedicare Part DPart D prescriptionsManufacturers of pharmaceuticalsPrescribingAnticoagulantsPhysiciansDrugsPart DEducational materialsSectional analysisStudy limitationsConsulting feesAssociation
2015
Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study)
Gupta A, Chui P, Zhou S, Spertus JA, Geda M, Lorenze N, Lee I, Onofrio G, Lichtman JH, Alexander KP, Krumholz HM, Curtis JP. Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). The American Journal Of Cardiology 2015, 116: 1-7. PMID: 25937348, PMCID: PMC4466069, DOI: 10.1016/j.amjcard.2015.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsBody Mass IndexCohort StudiesFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPrevalenceRecombinant ProteinsRisk AssessmentRisk FactorsSex DistributionTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsExcess dosingAcute myocardial infarctionCoronary interventionMultivariable analysisMyocardial infarctionUnderwent Percutaneous Coronary InterventionLower body weightOlder patientsYounger patientsUnfractionated heparinMedical recordsUnivariate analysisAnticoagulant agentsAnticoagulant drugsBody weightPatientsDosingYounger ageLogistic regressionYoung womenAnticoagulantsGender-based differences